Dylan Beynon
About Dylan Beynon
Dylan Beynon is the Founder and CEO of Mindbloom, a company that provides psychedelic therapy sessions and has conducted significant clinical studies in the field. He has a background in entrepreneurship and decision theory from The Wharton School and has co-founded multiple ventures, focusing on increasing access to mental health treatments.
Work at Mindbloom
Dylan Beynon has served as the Founder and CEO of Mindbloom since 2018. Under his leadership, Mindbloom has conducted the largest peer-reviewed clinical study in the history of psychedelic therapy, focusing on depression and anxiety. The company provides approximately 250,000 psychedelic therapy sessions annually and operates in 38 states, reaching 86% of the American population. Mindbloom has also received the Tony Hsieh Award for its transformational culture and innovative approach to mental health treatment.
Education and Expertise
Dylan Beynon graduated from The Wharton School of the University of Pennsylvania with a Bachelor of Science in Economics. His studies included concentrations in Entrepreneurship and Decision Theory, along with a minor in Consumer Psychology. He received a full Trustee Scholarship, highlighting his academic achievements. His educational background supports his expertise in business growth and healthcare innovation.
Background
Dylan Beynon grew up in a family impacted by mental illness, having lost both his mother and sister to severe mental health issues and addiction. This personal experience has driven his commitment to increasing access to psychedelic medicines. He began his healing journey in 2009 through psychedelic therapies and discovered ketamine therapy in 2018, which he describes as life-changing.
Previous Work Experience
Before founding Mindbloom, Dylan Beynon co-founded and served as Chief Growth Officer at Mighty from 2013 to 2018. He also co-founded Voter's Friend, where he was Head of Marketing until its acquisition by Democracy.com in 2013. Earlier in his career, he worked as a Growth Product Manager at Hotlist from 2011 to 2012. His diverse experience in startups and growth strategies has contributed to his success in the healthcare sector.
Achievements and Recognition
Dylan Beynon has been recognized as one of the Top 100 Most Influential People in Psychedelics and as a Top 25 Consumer HealthTech Executive. He has led Mindbloom to significant milestones, including the largest clinical study in psychedelic therapy and the provision of extensive therapy sessions. His leadership has earned Mindbloom the Tony Hsieh Award for creating a transformational company culture.